Key result
A workshop on stroke primary prevention highlighted the need for risk assessment, novel treatments like the polypill, and addressing methodological barriers in future trials.
This workshop summary outlines the critical needs, methodological challenges, and opportunities in designing future primary stroke prevention trials.
Does not support practice changes; leaves open whether polypill or refined risk tools improve primary stroke prevention in future trials.
Most ( approximately 70%) of strokes are first-ever strokes, and hence to substantially reduce the neurological burden, primary prevention is crucial. Here, highlights of the National Institute of Neurological Disorders and Stroke workshop "Stroke Risk Assessment and Future Stroke Primary Prevention Trials" held January 12-13, 2004 are summarized. The Workshop discussions focused on stroke risk assessment; the high-risk vs. population-based approaches to primary prevention; desirable characteristics of candidate treatments and potential novel treatments, such as the 'polypill'; subclinical disease as risk assessment tool and as surrogate outcome, and methodological issues in stroke primary prevention trials. The importance of assessing cognitive decline as an important consequence of covert and overt vascular injury of the brain was emphasized. The scientific or logistic barriers to stroke primary prevention trials are challenging, but are not insurmountable.
No takes yet. Share an insight, caveat, or question.
Radziszewska et al. (2005) conducted a review in Stroke. A workshop on stroke primary prevention highlighted the need for risk assessment, novel treatments like the polypill, and addressing methodological barriers in future trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: